Key result
PPARα activation or overexpression ameliorated doxorubicin-induced cardiotoxicity and reduced mitochondria-dependent apoptosis by directly upregulating MEOX1.
Why the study?
Doxorubicin causes serious cardiotoxicity, and while PPARalpha has known cardioprotective effects, its role in doxorubicin-induced cardiotoxicity has been rarely reported.
Does PPARα activation prevent doxorubicin-induced cardiotoxicity in preclinical models?
Does PPARα activation prevent doxorubicin-induced cardiotoxicity in preclinical models?
p-value: p=<0.05
PPARα activation ameliorates doxorubicin-induced cardiotoxicity by reducing mitochondria-dependent apoptosis via MEOX1 regulation, presenting a potential therapeutic target.
No takes yet. Share an insight, caveat, or question.
PPARα activation may mitigate doxorubicin cardiotoxicity in animals; hypothesis-generating and requires clinical trials before any practice implications.
Wang et al. (2020) studied Doxorubicin-induced cardiotoxicity. PPARα activation (fenofibrate/Wy-14643) or overexpression (rAAV9-PPARα) vs. Doxorubicin alone or control was evaluated on Cardiac function and mitochondria-dependent apoptosis (p=<0.05). PPARα activation or overexpression ameliorated doxorubicin-induced cardiotoxicity and reduced mitochondria-dependent apoptosis by directly upregulating MEOX1.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: